Our mission is to transform the way we treat cancer through a novel gene therapy approach that prevents resistance seen with current therapies, exhibits remarkable cancer-specificity, and reprograms cancer cells into immunotherapy engines.

Rather than inhibit the main culprits behind the top cancers affecting men and women, we harness their function: to transcribe genes. Our proprietary polynucleotide therapeutic recruits these cancer-causing transcription factors to drive expression of a multimodal therapy that recruits anti-tumor immune cells and inhibits key components of the immunosuppressive tumor microenvironment.

We intend to solve three of the biggest hurdles in solid tumor immunotherapy and prostate cancer therapy: resistance, recurrence, and immunosuppression